- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03201393
Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)
A Single Site, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of Low-Dose Naltrexone and Acetaminophen Combination vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
North Miami, Florida, United States, 33181
- Annette C. Toledano, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient is a male or female 18 years of age or older.
- A clinical diagnosis of nonmalignant, chronic low back pain (CLBP). LBP, as defined by Quebec Task Force in class 1 - pain without radiation and class 2 - pain with proximal radiation above the knee. CLBP is defined as being present for at least several hours a day, at least half the days in the previous 6 months, and being the principal pain condition. (In accordance with the NIH 2013 Task Force on Research Standards for Chronic Low Back Pain).
- The 24-hour average pain intensity (API) mean score for the baseline period is ≥ 4 and ≤ 8, [measured on the 11-point (0-10) numeric rating scale (NRS)] with each individual score ≥ 3. In addition, the Oswestry Disability Index (ODI) score during the Randomization Visit is ≥ 30% and ≤ 60%.
5. The patient agrees to refrain from taking opiate medications from Visit 1 to 7 days after the last dose of the study drug.
6. The patient agrees to limit their rescue pain medications to acetaminophen 2000 mg per day for the duration of the study.
7. The patient is willing and able to discontinue use of non-pharmacological pain management modalities (e.g. TENS, physical therapy, chiropractic manipulations, biofeedback, and acupuncture) for the duration of the study.
8. The patient has been taking a stable dose of a medication with pain prevention potential for at least 6 weeks prior to the screening visit and agrees to not start, stop, or change the dose of any medication with pain prevention potential during the study period. (E.g., tricyclic antidepressants, anticonvulsants, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), herbal preparations (e.g. feverfew or St. John's wort)). Botulinum toxin injections and steroid injections to the spine must be discontinued six months prior to Visit 1.
9. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA.
10. The patient agrees not to undergo any elective surgery, including spine surgery or injections to the spine (e.g. botulinum toxin, steroid, etc.) for the duration of the study.
11. The Female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative serum pregnancy test, be non-lactating, and commit to using adequate and reliable contraception throughout the study (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). Male patients must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after the study.
Exclusion Criteria:
- The patient has any condition consistent with Quebec Task Force Classification 3-11.
- The patient has another painful condition that may require analgesic medications, occurring regularly or intermittently (e.g. menstrual pain, carpal tunnel syndrome, arthritis, tendinitis, etc.).
The patient has concomitant migraine unless he/she treats migraine attacks only with ergotamine or triptans.
4. Regular use of the following medications for any reason: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antipsychotic drugs, monoamine oxidase inhibitors, muscle relaxants, blood thinning medications (e.g., warfarin or heparin), or cannabinoids. Low-dose aspirin for cardiovascular disease prophylaxis is permitted.
5. Diagnosis of any concurrent medical or psychiatric condition; this includes, chronic unstable debilitating diseases such as Parkinson's disease, multiple sclerosis, cancer, significant renal impairment, significant hepatic impairment, etc.
6. The patient has a history or diagnosis of moderate-to-severe hepatic or renal impairment (>2 × the upper limit of normal [ULN] for alanine transaminase or aspartate transaminase. ≥1.5 × ULN for Alkaline Phosphatase, bilirubin, BUN, or Creatinine). (Patients with elevated bilirubin level due to Gilbert's syndrome are allowed).
7. The patient has a history of the previous 5 years of abuse of any drug, prescription, illicit, or alcohol.
8. The Female patient is pregnant or breastfeeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose.
9. The patient has known-hypersensitivity to components of the investigational drug.
10. Participation in another study with an investigational drug within 30 days before Visit 1 or during the study.
11. The patient is in the opinion of the investigator, unsuitable to participate in this study for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Twice a day
|
Experimental: Low-Dose Naltrexone and Acetaminophen Combination
|
Twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from baseline in mean 7-day, 24-hour Worst Pain Intensity (WPI).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime.
The WPI score is measured on the 11-point (0-10) Numeric Rating Scale (NRS), (0=no pain, 10=worst possible pain).
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from baseline in mean 7-day, 24-hour Average Pain Intensity (API).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly API score will be derived from assessments recorded by patients daily at bedtime.
The API score is measured on the 11-point (0-10) NRS.
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
Proportion of patients with 50% or more reduction in 7-day, 24-hour Worst Pain Intensity (WPI).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly WPI score will be derived from assessments recorded by patients daily at bedtime.
The WPI score is measured on the 11-point (0-10) NRS.
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The change from baseline in mean 7-day, 24-hour Right Now Pain Intensity (NPI).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly NPI score will be derived from assessments recorded by patients daily at bedtime.
The NPI score is measured on the 11-point (0-10) NRS.
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The change from baseline in mean 7-day, 24-hour Pain-Related Interference (PRI) with day-to-day activities.
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly PRI score will be derived from assessments recorded by patients daily at bedtime.
The PRI score is measured on the 11-point (0-10) NRS.
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The change from baseline in mean 7-day, 24-hour pain-related sleep interference (PRSI).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
The mean weekly PRSI score will be derived from assessments recorded by patients daily at bedtime.
The PRSI score is measured on the 11-point (0-10) NRS.
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
Change from baseline in the mean number of rescue medications used.
Time Frame: From baseline to the last 7 days of the 12-week treatment period.
|
Rescue medications use will be derived from daily recordings by patients.
|
From baseline to the last 7 days of the 12-week treatment period.
|
Change from baseline in the mean Oswestry Disability Index (ODI).
Time Frame: From baseline to the last 7 days of the 12-week double-blind treatment period.
|
Patients will complete the ODI instrument during site visits (%).
|
From baseline to the last 7 days of the 12-week double-blind treatment period.
|
Change from baseline in the mean Pittsburgh Insomnia Rating Scale-20 (PIRS-20).
Time Frame: From baseline to the last 7 days of a 12-week double-blind treatment period.
|
Patients will complete the PIRS-20 instrument during site visits (0-60).
|
From baseline to the last 7 days of a 12-week double-blind treatment period.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the proportion of patients who experienced adverse events.
Time Frame: Completion of the treatment period at 12 weeks.
|
Defined as any untoward medical occurrences, regardless of their suspected cause.
|
Completion of the treatment period at 12 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Annette Toledano, M.D., Allodynic Therapeutics, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Back Pain
- Low Back Pain
- Radiculopathy
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
- Acetaminophen
Other Study ID Numbers
- ANODYNE-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Low Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Iran University of Medical SciencesNot yet recruitingLow Back Pain | Chronic Low-back Pain | Chronic Non-specific Low Back Pain | Cupping Therapy
-
Federal University of Minas GeraisRecruitingBack Pain | Low Back Pain | Chronic Low-back Pain | Back Pain Lower Back ChronicBrazil
-
Federal University of ParaíbaCompletedChronic Low Back Pain | Nonspecific Chronic Low Back Pain
-
University of Colorado, BoulderNational Institutes of Health (NIH); Radiological Society of North America; Psychophysiologic... and other collaboratorsCompletedChronic Pain | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
Presidio Medical, IncRecruitingChronic Pain | Chronic Low-back PainAustralia
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
Dan RhonNational Center for Complementary and Integrative Health (NCCIH); 59th Medical... and other collaboratorsRecruitingLow Back Pain | Chronic Pain | Surgery | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Texas Woman's UniversityTexas Physical Therapy AssociationCompletedLow Back Pain | Chronic Low Back Pain | Subacute Low Back PainUnited States
Clinical Trials on Low-dose naltrexone and acetaminophen combination
-
Allodynic Therapeutics, LLCCompletedMigraine With or Without AuraUnited States
-
Allodynic Therapeutics, IncCompleted
-
Allodynic Therapeutics, LLCCompletedMigraine With or Without AuraUnited States
-
Yale UniversityNational Institutes of Health (NIH)Completed
-
Jinnah Postgraduate Medical CentreCompleted
-
University of Alabama at BirminghamWithdrawn
-
Paolo MannelliAlkermes, Inc.CompletedLow Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (BUP/NXT-VIVI)Opiate DependenceUnited States
-
Hadassah Medical OrganizationJerusalem Institute for Child DevelopmentUnknownPervasive Developmental DisorderIsrael
-
Washington University School of MedicineCompletedFrontal Fibrosing Alopecia | Lichen PlanopilarisUnited States
-
AgelessRxSuspended